Listen: Talkspace’s civic experiment, Illumina’s FTC headache, & remembering Gilead’s John Martin
Can an app replace in-person therapy? Is Illumina too big to Grail? And is another CRISPR patent dispute in the cards?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Mario Aguilar joins us to discuss a fascinating experiment in Nevada, where one city is giving its residents free access to a therapy app — and getting a mixed reception. Then, New York University antitrust expert Eleanor Fox calls in to discuss the case of Illumina, the genome sequencing giant whose grand plans keeping running afoul of the Federal Trade Commission. Finally, we embark on a lightning round, covering the latest Covid-19 vaccine news, biotech’s biggest events over the next three months, and the death of a pioneering Gilead Sciences executive.
